Targeting CD137 enhances the efficacy of cetuximab
Holbrook E K Kohrt, Alexander Dimitrios Colevas, Roch Houot et al. · Journal of Clinical Investigation · 2014
Treatment with cetuximab, an EGFR-targeting IgG1 mAb, results in beneficial, yet limited, clinical improvement for patients with head and neck (HN) cancer as well as colorectal cancer (CRC) patients with WT KRAS tumors. Antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells contributes to the efficacy of cetuximab. The costimulatory molecule CD137 (4-1BB) is expressed following NK and memory T cell activation. We found that isolated human NK cells substantially increased expression of CD137 when exposed to cetuximab-coated, EGFR-expressing HN and CRC cell lines. Furthermore, activation of CD137 with an agonistic mAb enhanced NK cell degranulation and cytotoxicity. In multiple murine xenograft models, including EGFR-expressing cancer cells, HN cells, and KRAS-WT and KRAS-mutant CRC, combined cetuximab and anti-CD137 mAb administration was synergistic and led to complete tumor resolution and prolonged survival, which was dependent on the presence of NK cells. In patients receiving cetuximab, the level of CD137 on circulating and intratumoral NK cells was dependent on postcetuximab time and host FcyRIIIa polymorphism. Interestingly, the increase in CD137-expressing NK cells directly correlated to an increase in EGFR-specific CD8+ T cells. These results support development of a sequential antibody approach against EGFR-expressing malignancies that first targets the tumor and then the host immune system.
Cited by 160 works. doi:10.1172/jci73014 Open-access PDF
Authors
- Holbrook E K Kohrt
- Alexander Dimitrios Colevas
- Roch Houot
- Kipp Weiskopf
- Matthew Jordan Goldstein
- Peder J. Lund
- Antonia M. S. Müller
- Idit Sagiv-Barfi
- Aurélien Marabelle
- Ruth Lira
- Emily Troutner
- Lori Richards
- Amanda Rajapaska
- Jonathan P. O. Hebb
- Cariad Chester
- Erin Waller
- Anton Ostashko
- Wen‐Kai Weng
- Lieping Chen
- Debra Katherine Czerwinski
References
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
- Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
- Immunostimulatory monoclonal antibodies for cancer therapy
- The biology of human natural killer-cell subsets
- Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy
- FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype
- Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells
- Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
- Contact-dependent Stimulation and Inhibition of Dendritic Cells by Natural Killer Cells
- Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.